Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 2
2003 5
2004 10
2005 10
2006 8
2007 10
2008 9
2009 9
2010 12
2011 10
2012 8
2013 15
2014 10
2015 10
2016 5
2017 9
2018 10
2019 9
2020 10
2021 18
2022 17
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

191 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean huei chuan sung[Author] (45 results)?
Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma.
Sun YF, Wu L, Liu SP, Jiang MM, Hu B, Zhou KQ, Guo W, Xu Y, Zhong Y, Zhou XR, Zhang ZF, Liu G, Liu S, Shi YH, Ji Y, Du M, Li NN, Li GB, Zhao ZK, Huang XY, Xu LQ, Yu QC, Peng DH, Qiu SJ, Sun HC, Dean M, Wang XD, Chung WY, Dennison AR, Zhou J, Hou Y, Fan J, Yang XR. Sun YF, et al. Among authors: sun hc. Nat Commun. 2021 Jul 2;12(1):4091. doi: 10.1038/s41467-021-24386-0. Nat Commun. 2021. PMID: 34215748 Free PMC article.
Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).
Sun HC, Zhou J, Wang Z, Liu X, Xie Q, Jia W, Zhao M, Bi X, Li G, Bai X, Ji Y, Xu L, Zhu XD, Bai D, Chen Y, Chen Y, Dai C, Guo R, Guo W, Hao C, Huang T, Huang Z, Li D, Li G, Li T, Li X, Li G, Liang X, Liu J, Liu F, Lu S, Lu Z, Lv W, Mao Y, Shao G, Shi Y, Song T, Tan G, Tang Y, Tao K, Wan C, Wang G, Wang L, Wang S, Wen T, Xing B, Xiang B, Yan S, Yang D, Yin G, Yin T, Yin Z, Yu Z, Zhang B, Zhang J, Zhang S, Zhang T, Zhang Y, Zhang Y, Zhang A, Zhao H, Zhou L, Zhang W, Zhu Z, Qin S, Shen F, Cai X, Teng G, Cai J, Chen M, Li Q, Liu L, Wang W, Liang T, Dong J, Chen X, Wang X, Zheng S, Fan J; Alliance of Liver Cancer Conversion Therapy, Committee of Liver Cancer of the Chinese Anti-Cancer Association. Sun HC, et al. Hepatobiliary Surg Nutr. 2022 Apr;11(2):227-252. doi: 10.21037/hbsn-21-328. Hepatobiliary Surg Nutr. 2022. PMID: 35464283 Free PMC article. Review.
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.
Shi GM, Huang XY, Wu D, Sun HC, Liang F, Ji Y, Chen Y, Yang GH, Lu JC, Meng XL, Wang XY, Sun L, Ge NL, Huang XW, Qiu SJ, Yang XR, Gao Q, He YF, Xu Y, Sun J, Ren ZG, Fan J, Zhou J. Shi GM, et al. Among authors: sun hc. Signal Transduct Target Ther. 2023 Mar 17;8(1):106. doi: 10.1038/s41392-023-01317-7. Signal Transduct Target Ther. 2023. PMID: 36928584 Free PMC article. Clinical Trial.
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Kim DU, Wasan H, Ducreux M, Bao Y, Boyken L, Ma J, Garfin P, Pant S; HERIZON-BTC-01 study group. Harding JJ, et al. Among authors: sun hc. Lancet Oncol. 2023 Jul;24(7):772-782. doi: 10.1016/S1470-2045(23)00242-5. Epub 2023 Jun 2. Lancet Oncol. 2023. PMID: 37276871 Clinical Trial.
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).
Yang Y, Sun J, Wu M, Lau WY, Zheng S, Wang XH, Chen X, Fan J, Dong J, Cai J, Chen M, Chen Y, Cheng Z, Dai C, Shan J, Du CY, Fang C, Hu H, Ji Z, Jia W, Li G, Li J, Li J, Liu C, Liu F, Ma Y, Mao Y, Niu Z, Shen J, Shi J, Shi X, Song W, Sun HC, Tan G, Tao R, Wang X, Wen T, Wu L, Xia J, Xiang BD, Yan M, Ying M, Zhang L, Zhang X, Zeng ZC, Zhang Y, Zhang Z, Zhou J, Zhou C, Zhou J, Zhou L, Zhou X, Zhu J, Zhu Z, Zhang Q, Li Q, Cheng S. Yang Y, et al. Among authors: sun hc. Liver Cancer. 2022 Jul 20;11(6):511-526. doi: 10.1159/000526038. eCollection 2022 Dec. Liver Cancer. 2022. PMID: 36589726 Free PMC article. Review.
Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version).
Wang H, Chen J, Zhang X, Sheng X, Chang XY, Chen J, Chen MS, Dong H, Duan GJ, Hu HP, Huang ZY, Jia WD, Jiang XQ, Kuang D, Li SS, Li ZS, Lu CL, Qin SK, Qiu XS, Qu LJ, Shao CK, Shen F, Shi GM, Shi SS, Shi YJ, Sun HC, Teng XD, Wang B, Wang ZB, Wen TF, Yang JM, Yang QQ, Ye SL, Yin HF, Yuan ZG, Yun JP, Zang FL, Zhang HQ, Zhang LH, Zhao JM, Zhou J, Zhou WX, Fan J, Chen XP, Lau WY, Ji Y, Cong WM; Chinese Society of Liver Cancer of Chinese Anti-Cancer Association; Digestive Disease Group of Chinese Society of Pathology, Chinese Medical Association; Chinese Society of Pathology of Chinese Anti-Cancer Association; Hepatic Surgery Group of Chinese Society of Surgery, Chinese Medical Association; Biliary Tract Tumor Committee of China Anti-Cancer Association; Chinese Society of Clinical Oncology. Wang H, et al. Among authors: sun hc. J Clin Transl Hepatol. 2023 Dec 28;11(7):1553-1564. doi: 10.14218/JCTH.2023.00118. Epub 2023 Jul 24. J Clin Transl Hepatol. 2023. PMID: 38161496 Free PMC article.
Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study.
Xu B, Dong SY, Bai XL, Song TQ, Zhang BH, Zhou LD, Chen YJ, Zeng ZM, Wang K, Zhao HT, Lu N, Zhang W, Li XB, Zheng SS, Long G, Yang YC, Huang HS, Huang LQ, Wang YC, Liang F, Zhu XD, Huang C, Shen YH, Zhou J, Zeng MS, Fan J, Rao SX, Sun HC. Xu B, et al. Among authors: sun hc. Liver Cancer. 2022 Nov 28;12(3):262-276. doi: 10.1159/000528034. eCollection 2023 Aug. Liver Cancer. 2022. PMID: 37601982 Free PMC article.
191 results